Ruxience
E261831
Ruxience is a biosimilar monoclonal antibody to rituximab used in the treatment of certain cancers and autoimmune diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ruxience canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2371049 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ruxience Context triple: [Rituxan, hasBiosimilar, Ruxience]
-
A.
REX
REX is a radio science experiment instrument aboard NASA's New Horizons spacecraft used to study the atmospheres and surfaces of planetary bodies through radio signal measurements.
-
B.
Vivanco
Vivanco is a Spanish-language surname of likely Iberian origin borne by various notable individuals.
-
C.
Xan
Xan is a short, informal diminutive of the given name Xander.
-
D.
Rosaliac
Rosaliac is a La Roche-Posay skincare line formulated to soothe, strengthen, and visibly reduce redness in sensitive, redness-prone skin.
-
E.
Arlanxeo
Arlanxeo is a global synthetic rubber company specializing in high-performance elastomer products for the automotive, construction, and industrial sectors.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ruxience Target entity description: Ruxience is a biosimilar monoclonal antibody to rituximab used in the treatment of certain cancers and autoimmune diseases.
-
A.
REX
REX is a radio science experiment instrument aboard NASA's New Horizons spacecraft used to study the atmospheres and surfaces of planetary bodies through radio signal measurements.
-
B.
Vivanco
Vivanco is a Spanish-language surname of likely Iberian origin borne by various notable individuals.
-
C.
Xan
Xan is a short, informal diminutive of the given name Xander.
-
D.
Rosaliac
Rosaliac is a La Roche-Posay skincare line formulated to soothe, strengthen, and visibly reduce redness in sensitive, redness-prone skin.
-
E.
Arlanxeo
Arlanxeo is a global synthetic rubber company specializing in high-performance elastomer products for the automotive, construction, and industrial sectors.
- F. None of above. chosen
Statements (39)
| Predicate | Object |
|---|---|
| instanceOf |
biosimilar medicinal product
ⓘ
monoclonal antibody ⓘ rituximab biosimilar ⓘ |
| hasActiveIngredient | rituximab ⓘ |
| hasATCCode | L01XC02 ⓘ |
| hasCommonAdverseEffect |
hypogammaglobulinemia
ⓘ
infections ⓘ infusion-related reactions ⓘ neutropenia ⓘ |
| hasContainerType | vial ⓘ |
| hasDrugClass |
anti-CD20 monoclonal antibody
ⓘ
antineoplastic agent ⓘ immunosuppressive agent ⓘ |
| hasEffectOnImmuneSystem | reduces B-cell mediated immune responses ⓘ |
| hasFormulation | concentrate for solution for infusion ⓘ |
| hasINN |
rituximab
ⓘ
linked to:
Rituxan
|
| hasMechanismOfAction | B-cell depletion ⓘ |
| hasPharmacologicalTargetCell | CD20-positive B lymphocytes ⓘ |
| hasRegulatoryType | biosimilar approval pathway ⓘ |
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasStrength | 10 mg/mL ⓘ |
| isAdministeredInSetting |
hospital
ⓘ
specialist infusion center ⓘ |
| isAdministeredWith |
premedication with antihistamine
ⓘ
premedication with antipyretic ⓘ premedication with glucocorticoid ⓘ |
| isBiosimilarTo |
MabThera
ⓘ
Rituxan ⓘ |
| isDevelopedBy | Pfizer ⓘ |
| isNotInterchangeableWith | rituximab products without appropriate regulatory designation ⓘ |
| isUsedForTreatmentOf |
certain autoimmune diseases
ⓘ
chronic lymphocytic leukemia ⓘ diffuse large B-cell lymphoma ⓘ follicular lymphoma ⓘ granulomatosis with polyangiitis ⓘ
linked to:
Wegener's granulomatosis
microscopic polyangiitis ⓘ non-Hodgkin lymphoma ⓘ rheumatoid arthritis ⓘ |
| targets |
CD20 antigen
ⓘ
linked to:
CD20 protein
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ruxience Description of subject: Ruxience is a biosimilar monoclonal antibody to rituximab used in the treatment of certain cancers and autoimmune diseases.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.